Navigation Links
Odyssey Thera Granted U.S. Patent for Animal Imaging
Date:12/12/2007

SAN RAMON, Calif., Dec. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation Assays (PCA) in whole animals: applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy." This is the twelfth patent issued for Odyssey Thera's PCA process.

The patent describes a method for detecting protein-protein interactions in living cells and animals. Protein interactions define the intricate biochemical networks in living cells, and are used at Odyssey Thera to monitor drug response. The invention makes it possible to monitor specific biochemical parameters, including the extent and kinetics of drug target modulation, in a live subject.

"This patent extends our broad estate in drug discovery technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "One of the most challenging aspects of drug discovery is transitioning drug candidates from the test tube, to native targets in living cells, and from there to live subjects. With this invention, drug discovery and development are achieved with a single system that faithfully monitors the activity of a drug at each step." Dr. Westwick continues, "Whole animal studies using fluorescence or luminescence detection are widely used in the pharmaceutical industry, but strategies were needed to increase the scope of biochemical activities that can be tracked. The approaches described here will significantly increase the value of live subject imaging efforts."

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for chronic diseases. Odyssey Thera is leveraging its proprietary pathway-based approach and human cell models to optimize drug development for its own programs and for its premier pharmaceutical company partners.

To learn more about Odyssey Thera visit http://www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadylâ„¢, ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS , With ... a trusted supplier in the weighing industry, to extending its expertise across the entire ... reactions, immunoassays, hybridizations and more, allowing for its customers to 'Do More' ...
(Date:6/19/2017)... ... 19, 2017 , ... As Vice President, Product Services, Mr. ... implementation, support, and client process and SOP development. , Mr. Guinter brings a ... roles for service providers and top-tier pharmaceuticals, and as an independent consultant supported ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... Tunnell ... for over 50 years. One of the biggest challenges faced by life sciences, biotech ... regulatory affairs services team is Kati Abraham , who is well known in ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):